Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, today announced the closing of a Series C funding round raising $105 million.
Neoadjuvant Chemoradiation Plus Immunotherapy Boosts Responses in Esophageal Cancer
SAN FRANCISCO — Neoadjuvant chemoradiotherapy with or without the investigational PD-1 inhibitor sintilimab significantly increased pathological complete response (pCR) rates compared with neoadjuvant chemotherapy plus